Natco Pharma gains 4% after launching generic Pomalyst in US market
News by Aliceblue News Desk
04 Mar 2026
Introduction
Leading pharmaceutical company launched generic Pomalidomide Capsules in the U.S. market with partner support, securing 180 days shared exclusivity based on FDA information.
Also Read: Middle East tensions: Safe-haven panic sends gold surging over 1% on Iran conflict
Share price movement of Natco Pharma
On March 4, 2026, Natco Pharma Ltd opened at ₹955.05, down 0.14% from its previous close of ₹956.40. The stock reached a high of ₹992.00 (3.72%) and a low of ₹955.05. By 11:25 AM, it traded at ₹957.70, up 0.14%, with a market cap of ₹17,153.35 crore.
NATCO Launches Generic Pomalidomide in US
Natco Pharma Limited announced the launch of Pomalidomide Capsules in the U.S. market with partner Breckenridge Pharmaceutical, Inc.. The product is a generic version of Pomalyst by Celgene.
Pomalidomide Capsules are indicated for adult multiple myeloma patients after at least two prior therapies. The drug is also approved for AIDS-related Kaposi sarcoma and HIV-negative adult Kaposi sarcoma patients.
The capsules are available in 1mg, 2mg, 3mg, and 4mg strengths. U.S. sales of Pomalyst were about USD 3.2 billion for twelve months ending September 2025. NATCO has 180 days shared exclusivity.
Stock performance of Natco Pharma for period of 1 week, 6 months, and 1 year
Natco Pharma Ltd declined 2.24% over the past week, gained 12.1% in the past six months, and rose 19.1% over the past one year.
Also Read: Bharat Dynamics, BEL, HAL lead rally on Mar 2; is more upside coming?
Shareholding pattern of Natco Pharma
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 49.50% | 49.50% | 49.60% |
| FII | 15.20% | 14.10% | 15.50% |
| DII | 5% | 6% | 6% |
| Public | 30.00% | 30.60% | 29.10% |
About Natco Pharma
Natco Pharma Limited (NSE: NATCOPHARM) develops generic, branded, and specialty pharmaceuticals, APIs, and crop protection products, with nine manufacturing sites and two R&D facilities in India.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Natco Pharma Limited share price rising today?
A: Natco Pharma Limited launched generic Pomalidomide Capsules in US with 180 days shared exclusivity; US sales were USD 3.2 billion.
Q: What is Natco Pharma Limited’s main business focus?
A: Natco Pharma Limited develops and manufactures generic, branded, specialty pharmaceuticals, APIs, and crop protection products for domestic and global markets.
Q: What are the 52-week high and low of Natco Pharma Limited stock?
A: Natco Pharma Limited stock recorded 52-week high of ₹1,059.60 and 52-week low of ₹660.05.
News Author
Aliceblue News Desk
